Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Femasys's $30M placement funds a U.S. launch and a pivotal trial as sales slip 44.5%

Femasys closed a $30M private placement to build a FemaSeed sales team and run the FemBloc pivotal trial. Q3 sales fell 44.5%, and the financing market around it is split between large IPOs and small, structured raises.

16 Nov 2026 · CompePharma editorial

What happened

Femasys (FEMY) reported third-quarter results on November 13, 2026. Total sales fell 44.5% to $404,597, which the company attributed to the timing of international FemBloc orders. U.S. sales rose slightly to $347,039. Net loss for the quarter was $4.56 million, and cash was about $23.9 million.

The more important event for the financing desk is the $30 million private placement that closed in mid-August. Femasys says the proceeds are meant to build out a U.S. commercial team for the FemaSeed fertility portfolio and to fund the pivotal trial of FemBloc. The company also reported FDA acceptance of a modular PMA approach for FemBloc and twelve actively enrolling FINALE trial sites.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →